| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Tacrolimus | FAERS: 9 | US FAERS | |
| 2 | Dabigatran | FAERS: 6 | US FAERS | |
| 3 | rofecoxib | FAERS: 4 | US FAERS | |
| 4 | Rosiglitazone | FAERS: 3 | US FAERS | |
| 5 | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide | FAERS: 2 | US FAERS | |
| 6 | Aspirin | FAERS: 2 | US FAERS | |
| 7 | Rivaroxaban | FAERS: 2 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 8 | Raloxifene Hydrochloride | FAERS: 1 | US FAERS | |
| 9 | Sumatriptan | FAERS: 1 | US FAERS | |
| 10 | apixaban | FAERS: 1 | US FAERS | |
| 11 | Afatinib | Canada Vigilance: 1 | Canada Vigilance | |
| 12 | Ofloxacin | OFFSIDES |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120266
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.